Mar­tin Shkre­li’s old com­pa­ny touts PhI­II win, guns for ac­cel­er­at­ed ap­proval

Three months af­ter re­brand­ing to shed the last of its ties to con­vict­ed “Phar­ma Bro” Mar­tin Shkre­li, Tra­vere Ther­a­peu­tics is putting its best foot for­ward with an up­beat Phase III analy­sis and plans to seek ac­cel­er­at­ed ap­proval in a rare kid­ney dis­or­der.

Tra­vere — for­mer­ly known as Retrophin — says its lead can­di­date sparsen­tan met the pre-spec­i­fied in­ter­im end­point in a study of 371 pa­tients who have fo­cal seg­men­tal glomeru­loscle­ro­sis, a dis­or­der where kid­neys’ fil­tra­tion breaks down and pro­teins leak in­to the urine. For many pa­tients, the dis­or­der leads to end-stage kid­ney dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER